Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul Fimognari"'
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0235405 (2020)
[This corrects the article DOI: 10.1371/journal.pone.0233335.].
Externí odkaz:
https://doaj.org/article/937ada9c97c5474c9847c3f48cc6d634
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0233335 (2020)
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®. It has activity against imipenem non-susceptible P
Externí odkaz:
https://doaj.org/article/827d302122f740b6930e84d99ad435a7
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 5, p e0233335 (2020)
PLoS ONE, Vol 15, Iss 5, p e0233335 (2020)
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®. It has activity against imipenem non-susceptible P